Article
Dr. Jack Cush reviews the News and Journal Reports from the past week on RheumNow.com.
All News
Article
In an Annals of Rheumatic Disease report, Italian investigators performed consecutive testing for SARS-CoV-2 (IgM and IgG) between 25 March to 25 May 2020 and compared test results between rheumatic disease (RMD) patients and the general population.
Article
Dr. Jack Cush reviews the news, tweets and journal articles from the past week on RheumNow. Let's dig into this week's 14 highlights.
Article
Hydroxychloroquine (HCQ) helped reduce recurrent maternal autoantibody-mediated congenital heart block (CHB) in fetuses, an open-label study suggested.
Article
A new article in Nature Medicine delineates how our understanding of COVID-19 infection has evolved over time, such that the infection outomes may be worsened by extrapulmonary manifestations; notably thrombotic, cardiac, renal, gastrointestinal hepatic, neurologic, and other complications.
Dr. John Cush
Tweet
A large Latin American SLE cohort was studied; 66 (5.6%) had familial SLE & 1110 (94.4%) sporadic SLE: Familial SLE was more often associated with discoid LE (OR 1.97) & CNS dz (OR 1.65), more MSK Dz. No group difference in Disease activity https://t.co/4Lak2q4QJn
Dr. John Cush
Tweet
Spanish registry of 3679 SLE pts finds 13.6% had polyautoimmunity (SLE plus another autoimmune Dz), Dx as thyroiditis (8%), Sjogrens (14%) secondary APS (14%). Incr odds in female, w/ ILD, Raynauds, SSA/SSB/RNP but LESS w/ antimalarial drugs [0.50] https://t.co/duTqepvmLR
Dr. John Cush
Tweet
FDA recommends health care professionals discuss naloxone with all patients when prescribing opioid pain relievers or medicines to treat opioid use disorder. Naloxone can be administered(+/- medical training) to help reduce opioid overdose deaths https://t.co/9B0hPhOm57
Dr. John Cush
Tweet
Belimumab FDA approved in kids (same dose 10mg/kg/IV) based on PLUTO trial - 93 SLE pts Rx w/ BEL or PBO. By wk 52, BEL had more SRI4 responders (52.8% vs 43.6%; OR 1.49;95% CI 0.64 to 3.46), more PRINTO/ACR 30 or 50 w/ stable PK. https://t.co/1xX0VLgl4q
Dr. John Cush
Tweet
FDA has issued draft guidance on Cannibis research: “Cannabis & Cannabis-Derived Compounds: Quality Considerations for Clinical Research, Draft Guidance for Industry,” outlines FDA’s current thinking on clinical research related cannabis-derived compounds https://t.co/ppvisN1oxU
Dr. John Cush
Tweet
Aurinia Announces U.S. Food and Drug Administration Acceptance of the Filing of
New Drug Application and Priority Review for Voclosporin for the Treatment of Lupus
Nephritis https://t.co/BMgqvuAUP5
Dr. John Cush
Tweet
RheumNow Podcast is Up! Listen to Fauci! Watch it here>> https://t.co/dHq3fP85Ip or Listen to the Podcast>> https://t.co/LdHO7fKUCp
Dr. John Cush
Tweet
Retrospective study of 603 myositis (IIM), 4047 RA and 4061 controls shows IIM has higher risk of CV events (HR 1.38) and MI [HR 1.61] but not CVA [HR 0.92]. The CV risk in IIM was equal to that in RA [HR 1.01]. IIM CV risk only present 1st 5 years https://t.co/EyD3GHv2YY
Victoria Shanmugam
Tweet
The preliminary #ACR20 schedule is here! Along with all your favorite plenary and networking sessions, the program will feature #Rheumatologist Dr. Anthony Fauci giving us a live update on #COVID19. @ACRheum #ACRConvergence - Where Rheumatology Meets
https://t.co/IWbiVw9PSP
Dr. John Cush
Tweet
Ghent Univ experience and literature review shows that diffuse and localized scleroderma occurs in 2.4 to 7.4% often with Raynauds (6/8), scleroderma pattern on nailfold videocapillaroscopy and SSc-specific autoantibodies https://t.co/zDgXsuKD3p
Dr. John Cush
Tweet
JAMA Internal Medicine reports that the number of hydroxychloroquine prescriptions increased from 367,346 to 683,999 (86.2%) from February to March 2020, and chloroquine prescriptions increased 158.6%, rising from 2,346 to 6,066 prescriptions. https://t.co/3MKsu5mOpx
Dr. John Cush
Tweet
Nice overview of Lupus Nephritis (III, IV, V) and biopsy results from the Renal Fellow Network https://t.co/tw1d5ldM04
Dr. John Cush
Tweet
SLE study from UK Clinical Practice registry matched 4343 SLE pts 1:6 controls; found lupus had 80% increased mortality risk (HR 1.8; CV, infx, Resp, accident/suicide). Higher risk w. younger onset & steroid. HCQ significantly lowered mortality risk (45%) https://t.co/c3IfiSydRr
Dr. John Cush
Tweet
Skin is often involved w/ ANCA+ vasculitis - 1184 AAV pt study shows skin involvement in 34% GPA; 28% MPA & 47% EGPA. Common are petechiae/purpura pruritus, urticaria, and maculopapular rash. AAV w/ skin Sxs have more systemic dz (GN, alveolar hemorrhage) https://t.co/egPdW2IEnu
Dr. John Cush
Tweet
#EULAR2020 #op0201 nationwide cohort study: higher incidence of dementia in SLE (3.9/1000pys) vs non-SLE ( 2.73/1000pys). HR 1.43. SLE risk of Alzheimer’s 1.4x &risk of vascular dementia 1.6x Higher than non-SLE cohort. Further studies to identify mechanism needed @RheumNow https://t.co/IL6KPvP320
